A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis Clinical Trial

Official title:

Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02267642
• Other study ID #: 2014.009.01
• Status: Completed
• Phase: Phase 2
• First received: October 10, 2014
• Last updated: January 23, 2017
• Start date: January 2015
• Est. completion date: January 2016

Study information

• Verified date: January 2017
• Source: AbGenomics B.V Taiwan Branch
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.

Description:

This is an open-label, multi-center, multi-dose phase II proof of principle trial to study the efficacy and safety of AbGn-168H in patients with moderate to severe active psoriatic arthritis. A minimum of 15 patients and a maximum of 20 will be recruited in 1 dosing group. For safety evaluation, the parameters to be assessed include physical examination, vital signs (blood pressure, heart rate, respiratory rate and body temperature), 12-lead ECG, safety laboratory tests, adverse events and tolerability. For efficacy evaluation, patients will be evaluated for proportion of subject reaching American College of Rheumatology 20 (ACR 20) in week 12 and proportion of subjects reaching ACR 20, ACR 50 and ACR 70 at different time points; Disease Activity Score 28 (DAS28) at different time points, as well as Target Lesion Psoriasis Severity Score (TLPSS) and static Physician Global Assessment (sPGA) for subjects with active skin lesions at different time point.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 2016
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria

1. Patient must give informed consent and sign an approved consent form prior to any study procedures

2. Age 18 to 75 (inclusive), males or females

3. Body weight < 140 kg

4. Subject has had a diagnosis of psoriatic arthritis for at least 6 months and currently meets the CASPAR criteria.

5. Patients must have moderate to severe active PsA at screening and baseline, defined as having greater than or equal to 3 tender (out of 68) and 3 swollen (out of 66) joints.

6. Patients must have at least one evaluable skin plaque, 2 cm in diameter, that can be followed with a target lesions score (scalp and groin lesions cannot be used), or documented psoriasis history.

7. Patients must have history of inadequate response or intolerance to NSAID or DMARD defined by the investigator.

8. If the patient is taking background corticosteroids, dose must be = 10 mg/day prednisone (or equivalent) and must have been at a stable dose for at least 4 weeks prior to screening.

9. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of psoriasis arthritis is permitted if the dose has been stable for at least 2 weeks prior to screening.

10. If the patient is taking methotrexate (MTX), the patient must have received methotrexate 7.5-25 mg/wk (p.o. or parenteral) for at least 12 weeks and at a stable dose for 4 weeks prior to screening. If the patient is not taking MTX, they must have been off the drug for at least 8 weeks prior to receiving the first dose (baseline).

11. Folic acid or folinic acid is required at least 1 mg per day or 5 mg per week for all patients taking MTX.

12. Whether or not the patient is taking methotrexate, all DMARDs (other than MTX) should be withdrawn at least 4 weeks prior to baseline (Visit 2) of first drug administration (4 weeks for etanercept, 8 weeks for infliximab, adalimumab, golimumab, certolizumab pegol and leflunomide, and 12 weeks for ustekinumab, c.f. Section 4.2.2). Subjects taking appremilast should discontinue the medication 2 weeks prior to receiving the first dose (baseline).

13. Females of childbearing potential must have a negative pregnancy test result prior to enrolment. Male and female of childbearing potential must agree to use a highly effective method of birth control during the study.

A female is considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal ligation and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy.

A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).

Exclusion criteria

1. History of malignancy in the past 5 years or suspicion of active malignant disease.

2. Evidence of current or previous clinically significant disease, medical condition other than psoriatic arthritis, or finding of the medical examination (including vital signs and ECG), that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This criterion provides an opportunity for the investigator to exclude patients based on clinical judgment, even if other eligibility criteria are satisfied.

3. Presence of another rheumatic or skin disease that, in the opinion of the investigator, could confound the ability to discern response.

4. HIV infection or a known HIV-related Malignancy.

5. Chronic or acute hepatitis B and C, or carrier status.

6. History of recurrent significant infection; known active bacterial, viral, fungal, mycobacterial infection, or any major episode of infection requiring hospitalization or treatment with iv antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.

7. Tuberculosis or a positive Quantiferon test for tuberculosis.

8. History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients.

9. Intake of restricted medications (c.f. Section 4.2.2) or other drugs considered likely to interfere with the safe conduct of the study.

10. Previous treatment with any cell-depleting therapies, including investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3). Patients with Orencia or Toclizumab treatment within 8 weeks, IVIG, Natalizumab or Prosorba Column treatment within 6 months, and anti-CD19 or anti-CD20 treatment within 1 year should be excluded.

11. Immunization with a vaccine within 4 weeks prior to baseline (Visit 2) of the first drug administration (e.g.; MMR, Varivax).

12. Current alcohol abuse.

13. Current drug abuse or positive drug screen at screening visit. Subjects with legitimate medically supervised uses of the drugs which are not excluded for other reasons (Section 4.2.2 of the protocol) can be enrolled.

14. Patients with any of the following laboratory values at screening and are considered clinically significant by the investigators:

• Haemoglobin < 9 g/dL, hematocrit, white blood cell count, absolute lymphocyte or platelet count < LLN (below the lower limit of the reference normal range), or absolute neutrophil < 1500/µL

• ALT, AST and/or total bilirubin > 2 x ULN

• Serum creatinine > 1.5 x ULN

15. Any clinically significant laboratory abnormalities other than those listed on Exclusion Criteria 14, based on the investigator's medical assessment at screening

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Intervention

Biological:
• AbGn-168H
monoclonal antibody

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	Metroplex Clinical Research Center, LLC	Dallas	Texas
United States	UC San Diego	La Jolla	California
United States	Justus J. Fiechtner, MD, PC	Lansing	Michigan
United States	Stanford University	Palo Alto	California
United States	Sarasota Arthritis Research Center	Sarasota	Florida
United States	Seattle Rheumatology Associates/Swedish Clinical Research	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
AbGenomics B.V Taiwan Branch

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subject reaching American College of Rheumatology score 20 (ACR20)		at 12-week after the first treatment
Secondary	Proportion of subjects reaching American College of Rheumatology score 20, 50 and 70 (ACR 20, ACR 50 and ACR70)		up to 24 weeks after the first treatment
Secondary	Disease Activity Score 28 (DAR28)		up 24 weeks after the first treatment
Secondary	Target Lesion Psoriasis Severity Score (TLPSS) for subjects with active skin lesions		up 24 weeks after the first treatment
Secondary	static Physician's Global Assessment (sPGA) for subjects with active skin lesions		up to 24 weeks after the first treatment
Secondary	Number of subjects with Adverse Event		up to 24 weeks after the first treatment
Secondary	Immunogenicity		up to 24 weeks after the first treatment
Secondary	Number of subject with abnormal clinical laboratory parameters		up to 24 weeks after the first treatment